# Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants

> **NCT05166421** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 224 (actual)

## Conditions studied

- Corona Virus Disease

## Interventions

- **BIOLOGICAL:** AZD7442
- **BIOLOGICAL:** AZD8895 (clonal cell line material)
- **BIOLOGICAL:** AZD1061 (clonal cell line material)
- **BIOLOGICAL:** AZD8895 (cell pool material)
- **BIOLOGICAL:** AZD1061 (cell pool material)

## Key facts

- **NCT ID:** NCT05166421
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-30
- **Primary completion:** 2023-07-19
- **Final completion:** 2023-07-19
- **Target enrollment:** 224 (ACTUAL)
- **Last updated:** 2024-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05166421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05166421, "Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05166421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*